Nivolumab will also allow the restoration of T-cell cytotoxicity and reactivation of effector immune responses in the tumor microenvironment by blocking the interaction between PD-1 and its ligands PD-L1/PD-L2 [4]. The gene discussed is CD274; the disease is neoplasm.